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Background: As the population ages, the burden on the healthcare system might increase and require changed
public health priorities. As infections are often more severe at older age, we rank notifiable infectious diseases (ID)
and describe trends of ID among the general population aged ≥65 years in Norway in order to inform public
health priorities for the aging population.
Methods: We included all eligible cases of the 58 IDs notified between 1993 and 2011 (n = 223,758; 12% ≥65 years)
and determined annual notification rates as the number of notified cases divided by the number of inhabitants of
the corresponding year. We ranked diseases using their average annual notification rate for 2007–2011. Trends in
notification rates from 1993 onwards were determined with a non-parametric test for trend. Using notification rate
ratios (NRR), we compared results in those aged ≥65 years to those aged 20–64 years.
Results: Invasive pneumococcal disease was the most common ID among the population ≥65 years (notification
rate 58/100,000), followed by pertussis (54/100,000) and campylobacteriosis (30/100,000). Most ID notification rates
did not change over time, though the notification rate of symptomatic MRSA infections increased from 1/100,000
in 1995 (first year of notification) to 14/100,000 in 2011.
Overall, fewer cases were notified among the population ≥65 years compared to 20–64 year olds (NRR = 0.73). The
NRR of each of the invasive bacterial diseases and antibiotic-resistant infections were above 1.5 (i.e. more common
in ≥65), while the NRR of each food- and waterborne disease, blood-borne disease/STI and (non-invasive) vaccine
preventable disease was below 1.
Conclusions: Based on our results, we emphasise the importance of focusing public health efforts for those
≥65 years on preventing invasive bacterial infections. This can be achieved by increasing pneumococcal and
influenza vaccine uptake, and risk communication including encouraging those aged ≥65 years and their caretakers
to seek healthcare at signs of systemic infection. Furthermore, good compliance to infection control measures,
screening of the at-risk population, and careful use of antibiotics may prevent further increase in antibiotic-resistant
infections.Background
In almost all Western countries, the proportion of the
population aged 65 years or older (≥65 years) is increasing.
In Norway, a 10% increase in the population ≥65 years has
been seen over the last 25 years, reaching almost 750,000 in
2011 (15% of the five million Norwegian inhabitants). The
increase is expected to continue due to longer survival and* Correspondence: anneke.steens@fhi.no
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reproduction in any medium, provided the orthe aging post-war baby boom generation [1]. With older
age, infections are often more severe due to factors such as
the presence of multiple underlying medical conditions,
weakened immune system (immunosenescence), concur-
rent use of different drugs (polypharmacy), delayed diagno-
sis, and/or delayed or diminished response to therapy [2-5].
Living in close proximity, such as in elderly homes and
nursing homes, facilitates transmission of infectious agents
among the older population [5,6]. An aging population may
therefore increase the burden on the healthcare system.
Furthermore, as the mortality rate resulting fromLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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1990s specifically for this older population [7], adapta-
tions in public health priorities might be needed.
Although much research has been done for those
≥65 years on specific IDs, like influenza [8], urinary tract
infection [9], bacterial meningitis [10], group B strepto-
coccal infection [11] and gastroenteritis [12], and on
vulnerable groups like long-term care residents [12,13], less
is known about IDs in the general population ≥65 years.
Furthermore, there is only limited information available on
time trends for different IDs. This information is especially
important with shifting demographics, age-specific behav-
ioural changes and changes in vaccine policy, to assist pol-
icymakers to choose appropriate public health responses.
As Norway has had a nationwide surveillance system in
place since the 1970s [14], we were able to describe IDs
and their trends among the general population ≥65 years in
Norway from 1993 to 2011. The results were then com-
pared to results of younger age groups. This study can be
used to inform public health priorities for the aging
population.
Methods
Design and study population
We used nationwide data from the Norwegian Surveillance
System for Communicable Diseases (MSIS) [14]. The
study population includes all Norwegian inhabitants
and the study period includes 1993 through 2011.
Data sources
MSIS has been in place since 1975 and is based at the
Norwegian Institute of Public Health (NIPH). Clinicians
and laboratories are obliged by law to report each case
of the 58 notifiable IDs to MSIS. Reports from clinicians
and laboratories on each case are matched by personal
identification number (see Additional file 1). According to
the MSIS regulations, the NIPH does not require ethical
approval for the use of notified data for this type of study.
As few changes in case definitions have been imple-
mented since 1993, we included all cases with a testing
date between January 1st 1993 and December 31st 2011,
who were registered before January 30th 2012. We only in-
cluded symptomatic cases, except for methicillin-resistant
Staphylococcus areus (MRSA), vancomycin-resistant en-
terococci (VRE) and chronic infections (hepatitis B and C,
HIV, syphilis and tuberculosis), for which we also included
asymptomatic cases. We excluded IDs for which no cases
among persons ≥65 years were notified during the study
period (anthrax, diphtheria, echinococcal disease, epi-
demic typhus, haemorrhagic fevers, leprosy, measles,
plague, poliomyelitis, rabies, relapsing fevers, SARS,
smallpox, trichinosis and yellow fever). Furthermore,
we excluded influenza and genital chlamydia because
only limited individual data is reported to MSIS.Publicly available demographic data for Norway (num-
ber of inhabitants at January 1st of each corresponding
year [15]) were used as the denominator.
Data analysis
Data were analysed in Stata 12 (Stata Corporation, USA)
and Excel (version 2010). We determined annual notifi-
cation rates as the number of notified cases divided by
the number of inhabitants of the corresponding year,
expressed per 100,000 persons. To rank diseases based
on their occurrence in recent years, we used data over
the period 2007–2011 and calculated the average annual
notification rate, in order to correct for yearly fluctua-
tions. To investigate general patterns in IDs, we deter-
mined the percentage of IDs per predefined ID category
(see Table 1). The category ‘invasive bacterial diseases’
was defined based on isolation of bacteria from blood or
other sterile site. The vaccine preventable diseases category
only comprised diseases of the childhood immunisation
program, excluding the invasive bacterial diseases.
Using stratified analyses for the age-groups <5, 5–19,
20–64 and ≥65 years, we compared ID notification rates
in those ≥65 years with the younger population. We cal-
culated annual notification rate ratios (NRR) by dividing
the notification rate among persons ≥65 years by the no-
tification rate in those 20–64 years. The average annual
NRR was calculated for the period 2007–2011.
We determined trends in ID notification rates from 1993
or since the year a disease became notifiable (see Footnote
3 to Table 1) and onwards, by using a non-parametric test
for trend with α = 0.01. The test for trend is an extension of
the Wilcoxon rank-sum test by Cuzick [16]. Only diseases
with a notification rate of at least 9/100,000 in the popula-
tion ≥65 years during 2007–2011 were investigated in more
detail, as well as tuberculosis and VRE. This cut off was
chosen based on a general conception of the burden of IDs
in relation to the epidemiological situation in Norway.
Tuberculosis was included because of the former high
notification rate (>9/100,000 before 2000) while VRE was
included due to the current high notification rate (>9/
100,000 in 2011).
We determined reported place of infection, hospital-
isation status, severity of infection, reason for testing,
type of laboratory sample, serotype (if relevant), sex and
ethnicity for IDs with an notification rate ≥9/100,000, as
well as for tuberculosis and VRE (see Additional file 1).
For MRSA, in addition to the division of (asymptomatic)
carriage and (symptomatic) infections, we determined the
median number of severe infections, defined as an infection
in inner organs or a systemic infection. We classified infec-
tions into healthcare associated, community-acquired or
imported, based on reported information on outbreaks in
healthcare settings, work (healthcare personnel), living con-
ditions (nursing home) and place of infection (see for more
Table 1 Age-specific average annual frequency and notification rates of IDs in Norway in 2007 to 2011
Notifiable infectious disease* Average annual frequency Average annual notification rate (range)/100,000 inhabitants NRR 7 (range)
Total ≥65 years Total <5 years 5-19 years 20-64 years ≥65 years 65+/20-64
Overall 15870 1792 332 (307–362) 330 (285–407) 330 (276–399) 351 (312–411) 253 (236–280) 0.7 (0.6-0.9)
Invasive bacterial diseases (IBD)
Pneumococcal IBD 818 411 17.1 (14.9-20.4) 13.0 (9.1-19.7) 2.3 (1.2-3.1) 12.1 (10.1-14.9) 58.1 (51.6-66.4) 4.8 (4.4-5.1)
Group B Streptococcal IBD 178 78 3.7 (3.4 -3.9) 14.1 (12.3-15.9) 0.2 (0.0-0.4) 2.0 (1.8-2.2) 11.0 (9.8-12.5) 5.6 (4.5-7.6)
Group A Streptococcal IBD 163 68 3.4 (2.8-3.6) 2.6 (1.0) 0.7 (0.4-0.9) 2.8 (2.1-3.2) 9.5 (8.8-10.7) 3.4 (2.7-4.5)
Haemophilus influenzae IBD 81 40 1.7 (1.5-1.8) 2.2 (1.4-3.4) 0.4 (0.2-0.5) 1.1 (0.8-1.4) 5.7 (4.4-7.0) 5.6 (3.5-8.9)
Meningococcal IBD 37 5.8 0.8 (0.6-0.9) 3.2 (2.3-4.1) 1.3 (0.9-2.0) 0.3 (0.3-0.4) 0.8 (0.3-1.1) 2.4 (1.0-3.6)
Food- and waterborne diseases 1
Campylobacteriosis 2839 217 59.2 (55.0-60.9) 62.4 (47.7-77.7) 36.2 (31.1-41.6) 73.4 (70.5-75.6) 30.5 (25.1-38.3) 0.4 (0.4-0.5)
Salmonellosis 1485 125 31.0 (26.0-40.8) 48.2 (36.9-56.9) 22.4 (18.1-30.0) 35.3 (28.0-47.5) 17.6 (12.3-21.8) 0.5 (0.4-0.7)
Listeriosis 31 20 0.7 (0.4-1.0) 0.3 (0.0-0.7) 0.0 (0.0-0.0) 0.4 (0.1-0.7) 2.8 (2.3-4.2) 15.6 (3.8-37.5)
Enteropathogenic E. coli-enteritis 2 272 9.2 5.6 (2.3-9.3) 61.1 (15.2-115.9) 2.2 (0.8-3.2) 2.0 (1.8-2.2) 1.3 (0.4-2.2) 0.6 (0.2-1.0)
Giardiasis 192 9.0 4.0 (3.6-5.0) 7.9 (4.8-10.1) 3.4 (2.8-3.7) 4.5 (3.9-5.8) 1.3 (0.8-1.9) 0.3 (0.2-0.3)
Shigellosis 144 6.4 3.0 (2.7-3.3) 3.7 (1.9-5.5) 1.8 (1.4-2.4) 3.8 (3.3-4.7) 0.90 (0.3-1.4) 0.2 (0.1-0.4)
Paratyphoid fever 16 1.0 0.3 (0.2-0.4) 0.3 (0.0-0.7) 0.3 (0.0-0.9) 0.4 (0.2-0.5) 0.1 (0.0-0.4) 0.4 (0.0-1.1)
Yersiniosis 59 2.8 1.2 (1.1-1.5) 3.4 (2.2-4.4) 1.0 (0.7-1.3) 1.3 (1.0-1.7) 0.4 (0.0-0.7) 0.3 (0. 0–0.6)
Typhoid fever 17 0.2 0.4 (0.2-0.6) 0.6 (0.3-1.7) 0.5 (0.4-0.5) 0.4 (0.2-0.7) 0.0 (0.0-0.1) 0.0 (0.0-0.2)
Vaccine preventable diseases
Pertussis 4328 383 90.4 (66.3-115.5) 56.3 (42.8-63.8) 211.5 (162.0-277.6) 63.4 (44.0-82.1) 54.2 (34.8-70.4) 0.9 (0.7-1.0)
Mumps 3 16 1.4 0.3 (0.2-0.5) 0.1 (0.0-0.6) 0.3 (0.1-1.0) 0.4 (0.3-0.5) 0.2 (0.1-0.3) 0.6 (0.3-1.0)
Tetanus 1.0 1.0 0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.1 (0.0-0.3) ∞ (∞)
Antibiotic-resistant bacteria
MRSA infection 3, 4 420 92 8.7 (7.3-11.4) 11.0 (8.8-13.3) 6.5 (5.1-9.4) 8.2 (6.6-11.4) 13 (11.4-16.1) 1.6 (1.2-2.1)
MRSA carriage 3, 4 384 82 8.0 (5.6-9.9) 16.3 (8.6-21.4) 4.6 (1.5-6.6) 7.3 (4.9-9.2) 12.2 (10.6-14.8) 1.7 (1.2-2.7)
Vancomycin-resistant enterococci 3 51 33 1.0 (0.1-4.3) 0.1 (0.1-0.3) 0.1 (0.0-0.4) 0.6 (0.1-2.3) 4.5 (0.6-19.4) 6.5 (4.0-8.6)
Penicillin-resistant pneumococci 3 11 1.4 0.2 (0.0-0.5) 1.1 (0.0-3.5) 0.1 (0.0-0.2) 0.2 (0.0-0.4) 0.2 (0.1-0.3) 1.7 (0.4-4.0)
Zoonosis/vector-borne diseases
Lyme borreliosis 3 297 57 6.2 (5.1-7.3) 5.6 (4.6-6.2) 8.9 (6.3-10.9) 4.9 (3.6-6.4) 8.1 (6.3-9.8) 1.7 (1.5-1.9)
Tularaemia 66 10 1.4 (0.3-3.6) 0.7 (0.0-2.3) 1.0 (0.2-2.8) 1.5 (0.3-3.9) 1.4 (0.1-3.8) 0.8 (0.4-1.0)
HFRS 5/Nephropathia epidemica 40 4.6 0.8 (0.4-1.6) 0.1 (0.0-0.3) 0.3 (0.1-0.6) 1.2 (0.6-2.3) 0.7 (0.3-1.2) 0.7 (0.2-1.0)
Malaria 32 1.0 0.7 (0.6-0.8) 0.2 (0.0-0.3) 0.2 (0.1-0.3) 1.0 (0.9-1.2) 0.1 (0.0-0.4) 0.1 (0.0-0.4)
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Table 1 Age-specific average annual frequency and notification rates of IDs in Norway in 2007 to 2011 (Continued)
Blood-borne/STI
Hepatitis C 3, 6 2270 36 47.2 (33.7-70.5) 2.3 (1.0-4.8) 5.1 (4.0-7.0) 76.1 (53.6-114.1) 5.0 (4.6-5.8) 0.1 (0.1-0.1)
Hepatitis B (chronic carriage) 693 13 14.4 (14.3-17.4) 0.7 (0.0-1.4) 8.5 (6.4-11.0) 20.9 (15.7-24.9) 1.8 (1.0-2.3) 0.1 (0.1-0.1)
Gonorrhoea 266 4.2 5.5 (4.6-6.3) 0.1 (0.0-0.3) 1.4 (0.9-1.6) 8.7 (7.4-9.8) 0.6 (0.1-1.2) 0.1 (0.0-0.1)
Hepatitis A 36 3.0 0.7 (0.4-1.0) 1.1 (0.7-2.3) 0.9 (0.6-1.4) 0.7 (0.3-1.1) 0.4 (0.1-1.0) 0.6 (0.4-1.4)
HIV infection 256 2.6 5.3 (4.9-5.9) 0.9 (0.0-2.1) 0.6 (0.4-0.9) 8.6 (8.0-9.5) 0.4 (0.3-0.6) 0.0 (0.0-0.1)
AIDS 33 2.2 0.7 (0.4-0.9) 0.0 (0.0-0.0) 0.0 (0.0-0.2) 1.0 (0.6-1.4) 0.3 (0.0-1.0) 0.3 (0.0-1.0)
Hepatitis B (acute infection) 71 1.4 1.5 (0.6-2.6) 0.1 (0.0-0.3) 0.6 (0.1-1.3) 2.2 (0.9-3.8) 0.2 (0.0-0.4) 0.1 (0.0-0.2)
Syphilis 88 0.8 1.8 (1.2-2.6) 0.0 (0.0-0.0) 0.1 (0.0-0.6) 3.0 (1.9-4.4) 0.1 (0.0-0.3) 0.0 (0.0-0.1)
Other diseases
Tuberculosis 336 38 7.0 (6.5-7.5) 1.5 (0.7-2.1) 4.4 (3.5-4.6) 8.8 (7.7-9.7) 5.3 (4.5-6.9) 0.6 (0.5-0.9)
Encephalitis 179 17 3.7 (2.8-6.4) 8.8 (5.5-17.2) 2.4 (1.4-4.9) 3.9 (2.9-6.5) 2.4 (1.9-3.2) 0.6 (0.5-0.8)
Legionellosis 40 15 0.8 (0.7-1.0) 0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.9 (0.7-1.1) 2.1 (1.5-3.0) 2.3 (1.8-3.2)
Creutzfeldt Jacob 3 9.6 7.2 0.2 (0.1-0.3) 0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.1 (0.0-0.1) 1.0 (0.3-1.4) 12.3 (2.0-∞)
IDs = infectious diseases.
*Note that data for botulism, cholera, rubella and brucellosis are not presented, as no such cases aged ≥65 years occurred between 2007 and 2011 (notification rate = 0/100,000).
1: Note that food- and waterborne infections can have been transmitted in other modes than through food and water, such as via infected individuals and animals.
2: Enteropathogenic E.(Escherichia) coli-enteritis includes Haemolytic Uremic Syndrome.
3: For the following diseases, notification became mandatory or the last change in notification guidelines was implemented after 1993: Mumps, MRSA infections, Lyme borreliosis (1995); Creutzfeldt Jacob (1997); MRSA
carriage, vancomycin-resistant enterococci, penicillin-resistant pneumococci (2005); hepatitis C (2008).
4: MRSA =Methicillin-resistant Staphylococcus aureus.
5: HFRS = Haemorrhagic fever with renal syndrome.
6: Because hepatitis C became notifiable only since 2008, these results only include data of 2008–2011.
7: The notification rate ratio (NRR) was calculated by dividing the average notification rate in 2007–2011 among the population ≥65 years by the average notification rate among those aged 20–64 years. A NRR above
1 reflects a higher notification rate in the population ≥65 years compared to those aged 20–64 years, while a NRR below 1 reflects a lower NRR in the population ≥65 years.
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http://www.biomedcentral.com/1471-2334/14/57details: [17]). For VRE, we separated symptomatic infec-
tions from VRE found through screening based on the
reported indication of testing. For the more in-depth ana-
lyses, we excluded years for which more than 15% of data
on a specific variable were missing. Data are presented as
median (range).
Results
A total of 223,758 cases notified to MSIS between 1
January 1993 and 31 December 2011 were included in
this study. Of these, 25,812 (12%) were among those
≥65 years. Infections among this population were as
common in men as in women (48% male).
Infectious disease notification rates in the population
≥65 years during 2007–2011
Generally, of all included IDs for persons ≥65 years in
2007–2011 (n = 8962), invasive bacterial diseases were
most common (33% of the 65+ cases). Twenty-two per-
cent of IDs in those ≥65 years were food- or waterborne,
21% were vaccine preventable and 12% were caused by
antibiotic-resistant bacteria. Zoonoses and blood-borne
diseases/STIs were least common, making up only 4.1%
and 3.8%, respectively, of all cases ≥65 years.
Invasive pneumococcal disease was the most common
ID among those ≥65 years during the period 2007–2011
(average annual notification rate 58/100,000; n = 411 cases
on average per year), with 80% caused by serotypes in-
cluded in the recommended 23-valent polysaccharide
pneumococcal vaccine. Pertussis (54/100,000; n = 383) and
campylobacteriosis (30/100,000; n = 217) were the 2nd and
3rd most frequently notified IDs. Other common IDs
among those ≥65 years were salmonellosis (49% S. Enteriti-
dis, 15% S. Typhimurium), MRSA infection or carriage,
and invasive group B (Streptococcus agalactiae) or group A
(Streptococcus pyogenes) streptococcal disease (Table 1).
Comparison between the population ≥65 years and the
younger population during 2007–2011
Although 15% of the Norwegian population is ≥65 years
[15], only 11% of all notified cases from 2007 to 2011
were among those ≥65 years, resulting in an NRR of
0.73 (range 0.63-0.90). All invasive bacterial diseases, all
antibiotic-resistant infections, legionellosis, listeriosis, Lyme
borreliosis and prion diseases were more common in the
population ≥65 years than among those aged 20–64 years
(NRR > 1.0). Tetanus only occurred among those ≥65 years
since 2007 (NRR =∞), but was uncommon (on average 1
case per year). Food- and waterborne diseases (except lis-
teriosis), blood-borne diseases/STIs, and vaccine prevent-
able diseases were less common among persons ≥65 years
(NRR < 1). Therefore, while pertussis, campylobacteriosis
and salmonellosis were among the most common IDs af-
fecting the older population, they were more common inthose aged 20–64 years (NRR: 0.86, 0.41 and 0.51, respect-
ively). We observed no consistent age patterns among the
zoonoses and vector-borne diseases.
Time trends in annual ID notification rates since 1993
The annual notification rate in those ≥65 years remained
at the same level over time for most IDs, with the excep-
tion of pertussis, campylobacteriosis, salmonellosis, inva-
sive group B streptococcal disease, MRSA infections,
tuberculosis and VRE, which changed significantly over
time (Figure 1). While the test for trend was not signifi-
cant for invasive pneumococcal disease (p = 0.13), the
annual notification rate increased from ≤60/100,000 in
the years before 2002 to 78/100,000 in 2004 but de-
creased thereafter to 52/100,000 in 2011 (Figure 1A).
The pattern was similar for pertussis (Figure 1B); the an-
nual notification rate increased from <30/100,000 before
2003 to 76/100,000 in 2006 and decreased subsequently
to 35/100,000 in 2011.
The increase in campylobacteriosis (Figure 1C) was
only observed among infections that were acquired
abroad, with 34% (range 30–40) of infections among
those ≥65 years in 1997–2001 being acquired abroad,
compared to 44% (range 40–46) in 2007–2010. While
salmonellosis is also often travel-related, the notification
rate showed only a minor increase (Figure 1D) and the
percentage acquired abroad remained stable (median
68% [range 58–80]).
The notification rate of MRSA infections in the 65+
population increased from 1.0/100,000 at the start of
notification (1995), to 13/100,000 in 2007–2011 (Figure 1E).
The increase was almost equally observed among health-
care associated infections (52% [range 39–65] of the
infections), community acquired infections (24% [range
13-36]) and among infections that were acquired abroad
(20% [range13-38]). The notification rate of asymptomatic
MRSA carriage as well as the percentage of severe MRSA
infections did not change significantly during this period
(median percentage severe: 9% [range: 4.8-19]). The notifi-
cation rate of VRE increased from 0.4-0.7/100,000 be-
tween 2005 and 2009 to 1.7/100,000 in 2010 and 19/
100,000 in 2011 (Figure 1F). The percentage of asymp-
tomatic carriage increased from 44% between 2005 and
2009 to more than 80% from 2010 onwards. The number
of cases ≥65 years with symptoms increased from no more
than 4 before 2009 to 5 in 2010 and 8 in 2011.
The notification rate of invasive group B streptococcal
disease increased specifically in the population ≥65 years;
the NRR changed from 4.1 in 1993–1996 to 5.6 in
2007–2011 (Figure 1G). No corresponding change over
time could be observed in age at infection (78–79 years),
type of laboratory sample (≥94% from blood, except in
2006: 84%), requirement for hospitalisation (>90% hospi-
talised) or assumed place of infection (>95% in Norway).
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observed for tuberculosis, with the NRR decreasing from
2.5 in 1993–1996 to 0.62 in 2007–2011 (Figure 1H).
While tuberculosis was common among those ≥65 years
before 2000 (>9/100,000 per year), the annual notifica-
tion rate decreased to 5.3/100,000 in 2007–2011. The
percentage of patients ≥65 years that were born abroad
increased from 12% in 1997–2001 to 25% in 2007–2011.
Discussion
This study on notification rates of ID and trends over
19 years among the general Norwegian population
≥65 years shows that invasive bacterial diseases, and
specifically invasive pneumococcal disease, were mostB
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Figure 1 Trends in age-specific annual notification rates (lines) and n
A: invasive pneumococcal disease, B: pertussis, C: campylobacteriosis, D: sa
streptococcal disease (Streptococcus agalactiae), H: tuberculosis. Note the d
rate ratios. *Note that VRE infections and carriage are only notifiable sincecommon and occurred more often among older com-
pared to younger individuals. Furthermore, antibiotic-
resistant bacterial infections or carriage were more
common in this older population and notification rates
increased over time, particularly for MRSA and VRE.
Overall, the population ≥65 years had less notifiable IDs
than the younger population. Together with economic
evaluations, including the comparison of disability ad-
justed life-years between diseases [18,19], this study
should be used to inform public health priorities for the
aging population.
Generally, comparing notification rates of IDs can be
challenging because of differences in surveillance systems,
populations and country-specific infection probabilities asN
otification rate ratio
N
otification rate ratio
N
otification rate ratio
N
otification rate ratio
otification rate ratios (dots) of notified infectious diseases.
lmonellosis, E: MRSA infections, F: VRE*, G: invasive group B
ifferent Y-scales; both for the notification rates and for the notification
2005.
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testing policies, healthcare seeking behaviour or better clin-
ical recognition of diseases among older adults [20], which
could mask changes in incidences. Our nation-wide notifi-
cation data over a broad time-span allowed comparing no-
tification rates in different IDs and age-groups over time,
while taking aspects of these challenges into account. Still,
the notification rate is not necessarily similar to the true in-
cidence, as some cases never visit healthcare or are not no-
tified. The amount of underreporting may vary between
IDs and between age-groups; differential underreporting
would induce bias. There are no studies available that esti-
mate the sensitivity and representativeness of the system,
but there are no indications for systematic changes in noti-
fication in recent years. The fact that the NRR did not
change over time for most diseases indicated that age-
specific changes in notification policy, testing policy or clin-
ical recognition were unlikely.
Despite differences in surveillance systems across coun-
tries, our disease-specific results generally confirm observa-
tions in other countries, like the high notification rate of
invasive bacterial diseases in the population ≥65 years and
the increase in antibiotic-resistant bacteria in recent years
[21-24]. The high notification rate of invasive bacterial
diseases is likely to result from the more severe clinical
presentation among older adults, rather than more trans-
mission within this population. Older individuals are more
prone to develop invasive infections due to immunosenes-
cence [25], comorbidities, polypharmacy, and/or dimin-
ished response to antimicrobial therapy [2,4,5]. Delayed
recognition of infections due to atypical presentations in-
cluding the absence of fever in approximately 20% to 30%
of older persons with serious infections [4,26], leading to a
delayed start of therapy, is another reason why invasive
disease develops more often in older individuals. As severe
infections may lead to functional decline e.g. through ex-
acerbation of underlying health problems, it is important to
prevent infections and specifically severe disease in this
older population. Risk communication to older people and
their caregivers including encouragement to seek healthcare
promptly in case of signs of systemic infection can reduce
delays in starting therapy. Through vaccination against
pneumococcal infections, a large portion of cases with inva-
sive pneumococcal disease may be prevented, as 80% of
infections were caused by serotypes included in the recom-
mended 23-valent pneumococcal vaccine [27]. Although
vaccination has been available in Norway for those aged
≥65 years since the 1980s, vaccine sales data indicate an up-
take of only 15 to 25% (unpublished data NIPH). Preven-
tion of invasive bacterial diseases can also be achieved
through prevention of viral respiratory infections due to the
increased susceptibility to bacterial super infections during
an influenza infection [28,29]. It is known that the burden
of influenza is highest among the older population [8,19].We were unfortunately not able to include influenza in our
analysis, because of its different surveillance system.
The overall notification rate of IDs was lower in the
population ≥65 years compared to the younger popula-
tion. So, while older people are at higher risk for some
IDs, overall they had less notified IDs, specifically, less
possible food- and waterborne diseases (except listeri-
osis), blood-borne diseases/STIs, and (non-invasive) vac-
cine preventable diseases. Different sexual behaviour,
less interaction with the public [30] and reduced travel
activity for the population ≥65 years compared to the
younger population [31] might explain part of the lower
notification rate.
The changes in notification rates over time of invasive
pneumococcal disease and pertussis were likely the re-
sult of changes in vaccination policy. The decrease in
invasive pneumococcal disease coincided with the intro-
duction of pneumococcal vaccination in the childhood
immunisation program in 2006 and can be explained by
herd protection [32-35]. The recent decrease in pertussis
notifications coincided with the introduction of a booster
vaccination at 7 years of age since the school-year 2005–
2006. This suggests that the booster not only protects the
targeted age-groups, but also provides some protection
among older adults. Still, the notification rate of pertussis
remains high [36], suggesting transmission between age
groups.
The increase in MRSA and VRE is worrisome, even
though the notification rate in Norway is low compared
to other countries [37]. It is likely that the MRSA in-
crease resulted not only from a real increase, but also
from enhanced surveillance [17]. Nevertheless, the in-
crease in notification of symptomatic infections but not
of carriage, supplemented by a time-series analysis of
methicillin-sensible and -resistant cases [38], indicate
also a real increase in infections. This increase is likely
partly related to increased travelling and the high en-
demic state of MRSA in other parts of the world [17] as
well as increased transmission in Norway. The increase
in notified VRE since 2010 was partly due to increased
screening, specifically during hospital-based outbreaks
[39]. However, a real increase in VRE incidence sug-
gested by the slight increase in the number of cases with
a symptomatic VRE infection. The increases in MRSA
and VRE notification rates with no change in NRR show
that good compliance to infection control measures,
screening of at-risk populations, and careful use of anti-
biotics remain important for all age-groups.
Further exploration of factors that may have caused the
disease-specific changes in notification rates showed
an increased notification rate of campylobacteriosis ac-
quired in Europe. This might be the effect of increased
travelling abroad [31], which increases the possibility
of acquiring travel-related infections. Travel-related
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[40] increased much less or remained stable. These lat-
ter IDs were more often acquired outside Europe (data
not shown). The difference between campylobacterio-
sis and the other travel-related IDs therefore may
reflect more travels within Europe. Alternatively, as
the change in notification rate in younger age-groups
showed similar changes, the increase may reflect in-
creased campylobacter transmission within Europe.
The change in tuberculosis resulted from a decrease in
notification rate among those born in Norway. This re-
flects the rapid decrease in tuberculosis incidence in
Norway since the late 1940s [41], as tuberculosis in
older adults mainly results from reactivation of previ-
ous infections, and fewer Norwegian-born people with
a history of tuberculosis are still alive.
Conclusions
Based on our results we emphasise the importance of
focusing public health efforts for the ≥65 population on
preventing invasive bacterial infections and antibiotic-
resistant infections. Although overall the incidence of
IDs among those ≥65 years was lower than in younger
populations, the IDs that were more common among
the population ≥65 years might be more difficult to pre-
vent. Prevention of these IDs in the future should there-
fore be reinforced, as the population is aging further.
Preventing bacterial infections and stopping infections
from becoming invasive can be accomplished through
raising awareness of the importance of vaccination in
both the general population and among healthcare pro-
fessionals [42], and through risk communication includ-
ing encouraging older individuals and their caretakers to
seek healthcare at signs of systemic infection, for instance,
change of behaviour. Furthermore, improved prevention of
antibiotic-resistant infections through careful use of
antibiotics, good compliance to infection control mea-
sures, screening of the at-risk population, specifically in
hospitals and other healthcare settings, as well as inter-
national cooperation, may prevent further increase of these
infections.
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